We are live on ! Find out more
XFOR icon

X4 Pharmaceuticals
XFOR

43 hedge funds and large institutions have $114M invested in X4 Pharmaceuticals in 2019 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 20 increasing their positions, 1 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,900% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 1

500% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 3

266% more capital invested

Capital invested by funds: $31.1M → $114M (+$82.8M)

48% more funds holding

Funds holding: 29 → 43 (+14)

1.15% more ownership

Funds ownership: 0.89% → 2.04% (+1.2%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

Holders
43
Holders Change
+14
Holders Change %
+48.28%
% of All Funds
0.93%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
18
Increased
20
Reduced
1
Closed
3
Calls
$750K
Puts
–
Net Calls
+$750K
Net Calls Change
+$750K

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$15.2M
2
RCM
RA Capital Management
Massachusetts
+$14.6M
3
CAM
Cormorant Asset Management
Massachusetts
+$10.8M
4
O
OrbiMed
New York
+$10.6M
5
BI
BVF Inc
California
+$9.84M

Top Sellers

Rank Fund Capital Flow
1
Federated Hermes
Federated Hermes
Pennsylvania
-$1.19M
2
CHP
Cable Hill Partners
Oregon
-$5K
3
Barclays
Barclays
United Kingdom
-$4K
4
MAM
Meeder Asset Management
Ohio
-$3.05K
Name Holding Trade Value Shares
Change 		Change in
Stake
O
1
OrbiMed
New York
$14M +$10.6M +20,833 +201%
Fidelity Investments
2
Fidelity Investments
Massachusetts
$13.5M +$15.2M +30,000 New
CAM
3
Cormorant Asset Management
Massachusetts
$13.4M +$10.8M +21,255 +252%
RCM
4
RA Capital Management
Massachusetts
$12.9M +$14.6M +28,713 New
BI
5
BVF Inc
California
$8.71M +$9.84M +19,350 New
DM
6
Deerfield Management
New York
$8.47M +$9.57M +18,833 New
Vanguard Group
7
Vanguard Group
Pennsylvania
$7.84M +$7.4M +14,551 +506%
BlackRock
8
BlackRock
New York
$6.85M +$7.06M +13,888 +1,045%
NMC
9
NEA Management Company
Maryland
$5M – – –
PVMCV
10
Polaris Venture Management Co V
Massachusetts
$4.67M – – –
SHI
11
SV Health Investors
Massachusetts
$4.67M – – –
NLVP
12
New Leaf Venture Partners
New York
$4.28M +$4.83M +9,500 New
Millennium Management
13
Millennium Management
New York
$2.27M +$2.57M +5,055 New
Geode Capital Management
14
Geode Capital Management
Massachusetts
$1.71M +$1.71M +3,373 +784%
State Street
15
State Street
Massachusetts
$1.21M +$1.07M +2,108 +357%
SFM
16
Sphera Funds Management
Israel
$711K +$803K +1,580 New
First Eagle Investment Management
17
First Eagle Investment Management
New York
$536K +$254K +500 +72%
Goldman Sachs
18
Goldman Sachs
New York
$480K +$543K +1,068 New
OAM
19
Oxford Asset Management
United Kingdom
$426K +$481K +946 New
Northern Trust
20
Northern Trust
Illinois
$392K +$442K +869 New
Charles Schwab
21
Charles Schwab
California
$317K +$357K +703 New
Bank of New York Mellon
22
Bank of New York Mellon
New York
$210K +$237K +466 New
Susquehanna International Group
23
Susquehanna International Group
Pennsylvania
$178K +$201K +396 New
N
24
Nuveen
North Carolina
$177K +$200K +394 New
Wells Fargo
25
Wells Fargo
California
$170K +$185K +363 +2,420%
1
2

XFOR Hedge Fund Activity: Q2 2019 in Review

43 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in X4 Pharmaceuticals (XFOR) for Q2 2019, worth a combined $114M — up 266% from $31.1M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new XFOR positions and 3 closed out — a net gain of 15 holders — while 20 added to existing stakes and 1 trimmed.

The largest buyer was Fidelity Investments, opening a new position worth an estimated $15.2M. The largest seller was Federated Hermes, exiting entirely with an estimated $1.19M sold.

  • 43 institutional investors held X4 Pharmaceuticals (XFOR) as of Q2 2019, up from 29 in Q1 2019.
  • Funds reported $114M of X4 Pharmaceuticals stock for Q2 2019, up 266% quarter-over-quarter.
  • 18 funds opened new X4 Pharmaceuticals positions in Q2 2019 and 3 closed out, a net change of +15 holders.
  • The largest X4 Pharmaceuticals buyer in Q2 2019 was Fidelity Investments, an estimated $15.2M added.
  • The largest X4 Pharmaceuticals seller in Q2 2019 was Federated Hermes, an estimated $1.19M sold.

Based on aggregated 13F filings for Q2 2019.